The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

Disclosed herein is a non-covalent complex, comprising: a tetramer of a recombinant protein; and an agonist of a Stimulator of Interferon Gene (STING) protein or a pharmaceutically acceptable salt thereof, wherein the recombinant protein comprises a STING protein lacking a transmembrane domain (STINGΔTM protein). Additionally, provided is a vaccine composition, comprising a non-covalent complex and a pharmaceutically acceptable carrier, wherein the non-covalent complex comprises: a recombinant protein comprising a STINGΔTM protein and a tumor epitope; and an agonist of a STING protein or a pharmaceutically acceptable salt thereof. Further provided are methods of treating and preventing cancer using the disclosed complexes, pharmaceutical compositions, and vaccines.

Disclosed herein is a non-covalent complex, comprising: a tetramer of a recombinant protein; and an agonist of a Stimulator of Interferon Gene (STING) protein or a pharmaceutically acceptable salt thereof, wherein the recombinant protein comprises a STING protein lacking a transmembrane domain (STINGΔTM protein). Additionally, provided is a vaccine composition, comprising a non-covalent complex and a pharmaceutically acceptable carrier, wherein the non-covalent complex comprises: a recombinant protein comprising a STINGΔTM protein and a tumor epitope; and an agonist of a STING protein or a pharmaceutically acceptable salt thereof. Further provided are methods of treating and preventing cancer using the disclosed complexes, pharmaceutical compositions, and vaccines.

The present disclosure provides conjugates comprising a binding moiety and an immunomodulatory imide compound, e.g., substituted isoindoline compound, wherein the immunomodulatory imide compound is conjugated to a binding moiety via an optional linker. Also provided are compositions comprising the conjugates. The conjugates and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.

The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.